Price$4.88+1.80 (+58.41%)
12:00 PM05:45 PM
News · 26 weeks40+400%
2025-12-212026-06-14
Mix2590d
- SEC Filings9(36%)
- Insider9(36%)
- Other6(24%)
- Offering1(4%)
Latest news
25 items- PRBiotech Bulls Stampede as Clinical Wins and Milestones Fuel MomentumDENVER, June 16, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Multiple clinical-stage companies are delivering meaningful regulatory, clinical, and corporate milestones. From brain cancer drug development and cell therapy expansion to neurodegenerative disease programs and cardiovascular breakthroughs, investors were presented with a wave of catalysts that are driving enthusiasm across several emerging healthcare names. Traders appeared particularly focused on companies advancing toward late-stage clinical development, securing new regulatory clearances, or gaining broader visibility through public market events. Download the 24/7 Market News App here https://app.247mnn.com/ or on the A
- INSIDERDirector Boger Joshua S bought $3,000,000 worth of shares (955,414 units at $3.14) (SEC Form 4)4 - CervoMed Inc. (0001053691) (Issuer)
- SECCervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- PRCervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert SummitBOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, being held virtually on Monday, June 15, 2026. Presentation DetailsFormat: Fireside ChatDate: Monday, June 15, 2026Time: 7:00 – 7:30 AM ETWebcast Link: https://journey.ct.events/view/9162603c-eb01-4cb3-85b7-36814fad7928 The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://
- INSIDERSEC Form 4 filed by Director Zavrl Frank4 - CervoMed Inc. (0001053691) (Issuer)
- INSIDERSEC Form 4 filed by Director Sabbagh Marwan4 - CervoMed Inc. (0001053691) (Issuer)
- INSIDERSEC Form 4 filed by Director Quigley David4 - CervoMed Inc. (0001053691) (Issuer)
- INSIDERSEC Form 4 filed by Director Poulton Jeffrey V.4 - CervoMed Inc. (0001053691) (Issuer)
- INSIDERSEC Form 4 filed by Director Hollingsworth Jane H4 - CervoMed Inc. (0001053691) (Issuer)
- INSIDERSEC Form 4 filed by Director Gregoire Sylvie4 - CervoMed Inc. (0001053691) (Issuer)
- INSIDERSEC Form 4 filed by Director Boger Joshua S4 - CervoMed Inc. (0001053691) (Issuer)
- INSIDERSEC Form 4 filed by CEO & President Alam John J4 - CervoMed Inc. (0001053691) (Issuer)
- SECCervoMed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- PRCervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy BodiesAdditional funding will extend anticipated runway into second quarter of 2027 Strategic priority is to establish a partnership to advance neflamapimod into Phase 3 in dementia with Lewy bodies Anticipated pipeline milestones over next six months include obtaining 24-week biomarker and clinical data from Phase 2a trial evaluating neflamapimod in nonfluent variant primary progressive aphasia and initiation of EXPERTS-ALS Phase 2a trial Financing includes substantial participation from insiders and leading institutional healthcare investors BOSTON, June 10, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related b
- SECCervoMed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- SECCervoMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- SECSEC Form 10-Q filed by CervoMed Inc.10-Q - CervoMed Inc. (0001053691) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CervoMed Inc.SCHEDULE 13G/A - CervoMed Inc. (0001053691) (Subject)
- SECCervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- PRCervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy BodiesResults consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible Findings also correlate with previously reported results on neflamapimod's observed effects on a blood biomarker of neurodegenerative disease activity, providing additional evidence of neflamapimod's potential to act on the underlying disease process in dementia with Lewy Bodies (DLB) DLB is the second most common progressive dementia, affecting millions worldwide, and has no approved treatments in the United States or European Union BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Today at the 2026 AAN Annual Meeting i
- SECCervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- PRCervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual MeetingUpdate will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 trial design Additional data from MRI analyses will also be featured at 2026 American Academy of Neurology Annual Meeting later this month; findings demonstrate neflamapimod's potential positive impact on basal forebrain atrophy and functional connectivity Dementia with Lewy bodies (DLB) is the second most common progressive dementia, affecting millions worldwide, and has no approved treatments in the United States or European Union BOSTON, April 07, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO) (CervoMed or the Company), a clinical-sta
- SECCervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- SECCervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- PRCervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-PathologyNew analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer's disease (AD) co-pathology — experienced greater clinical benefit with neflamapimod in Phase 2b clinical trial PK/PD analyses of Phase 2b clinical data provide further insight into the drug plasma concentration levels of neflamapimod associated with a clinical effect Findings further support neflamapimod's potential to target the underlying cause of disease in DLB and the Company's patient enrichment strategy and dosing regimen for planned Phase 3 trial BOSTON, March 19, 2026 (GLOBE NEWSWIRE) -- This week, in an oral session at the AD/PD™ 2026 Conference in
CRVO FAQ
5 questionsWhere does CRVO stock trade?
CervoMed Inc. (CRVO) is listed on NASDAQ.What sector and industry is CRVO in?
CervoMed Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CRVO?
CervoMed Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2025-12-18. Recent price targets range from $1400.00 to $4500.00.What companies are similar to CRVO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare CRVO side-by-side with any of them on Quantisnow.How can I track CRVO on Quantisnow?
Quantisnow aggregates CervoMed Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRVO to receive live email and push alerts on every new disclosure.